This pilot study will explore whether treatment of eosinophilic inflammation in the esophagus is associated with an improved distensibility of the esophagus. Furthermore, previous studies of the esophagus using EndoFlip only measured distensibility of the distal esophagus, specifically the distal esophagus and esophagogastric junction. Eosinophilia in EoE has been demonstrated to affect both upper, middle and lower esophagus. The aim is to measure distensibility both proximal and distal, before and after treatment.
None
Secondary causes of esophageal eosinophilia has been excluded, such as eosinophilic GI diseases, celiac disease, Crohn's disease, esophageal infection, hypereosinophilic syndrome, drug hypersensitivity, vasculitis, pemphigus, connective tissue diseases, graft vs. host disease
Age < 18 or > 65 years
Contraindication for biopsy, such as presence of esophageal varices, coagulopathy
History of esophageal surgery, gastric or esophageal malignancy, anatomical abnormality, or major primary motility disorder (such as achalasia)
Patients presenting to the clinic and endoscopy who are undergoing endoscopy with endoflip
Cohort
Prospective
endoflip
Diagnostic testResolution of esophageal eosinophilia by a 2-month course of high dose PPI in patients will lead to improvement in esophageal distensibility, and thus should produce improvement in dysphagia symptoms.
Change in Esophageal Distensibility before and after treatment
1\. Measure the changes in esophageal distensibility before and after treatment with PPI in patients with esophageal eosinophilia
Change in eosinophilia or the number of eosinophils
4\. To correlate changes of esophageal mucosa eosinophilia with changes of lumen distensibility in the different segments of the esophagus
Click on the lead sponsor to view all of their trials.
